Dr. Duane Nash, Chairman

Duane Nash, M.D., J.D., M.B.A, joined Immunic’s board as its chairman in 2019. From 2012 to 2019, Dr. Nash served in various leadership roles at Vital Therapies (Nasdaq: VTL), most recently as its Chief Executive Officer. Additional roles included Medical Director, Executive Vice President, Chief Business Officer and President. Prior to joining Vital Therapies, Dr. Nash held various positions at Wedbush PacGrowth Life Sciences, an investment bank, where he worked from 2009 to 2012, most recently as Senior Vice President in Equity Research. Before that, he was a research analyst at Pacific Growth Equities, which was acquired by Wedbush in 2009.

Dr. Nash also practiced law from 2002 to 2008, most recently at the law firm of Davis Polk & Wardwell, where he focused on intellectual property litigation and corporate matters. Dr. Nash served on the board of directors of Aerpio Pharmaceuticals (Nasdaq: ARPO) from 2012 to 2017, and Akebia Therapeutics (Nasdaq: AKBA) from 2013 to 2018.

Dr. Nash earned a B.A. in biology from Williams College, an M.D. from Dartmouth Medical School, a J.D. from the University of California, Berkeley, and an M.B.A. from the University of Oxford. Dr. Nash completed his internship in general surgery at the University of California, San Francisco.

Dr. Jörg Neermann

Jörg Neermann, Ph.D., joined Immunic’s board in 2016. He is a Partner at the life science-focused investment firm of LSP and has served on numerous life sciences company boards (both private and public). In addition to the Immunic board, he currently is a member of the boards of Probiodrug AG (Halle, Germany, Euronext Amsterdam: PBD), ViCentra B.V. (Utrecht, The Netherlands), Eyesense AG (Basel, Switzerland) and Ventaleon GmbH (Gmünden, Germany).

Prior to joining LSP, Dr. Neermann was Managing Director at DVC Deutsche Venture Capital (the venture capital subsidiary of Deutsche Bank), where he built and ran its healthcare investment franchise. Prior to DVC, he started his venture capital career with Atlas Venture as an associate and investment manager.

During his career, he led and completed more than 80 financing transactions and was intimately involved in more than 15 M&A transactions and IPOs with a total transaction volume exceeding a billion euros.

Dr. Neermann studied biotechnology at the Technical University in Braunschweig, Germany, and the Massachusetts Institute of Technology in Cambridge, Mass., and holds a master’s degree and a Ph.D. in Biotechnology from the Technical University in Braunschweig, Germany. He also studied economics at the Technical University in Braunschweig, Germany, and at Harvard Business School.

Dr. Neermann brings to Immunic a strong scientific background and hands-on finance and investment expertise. He is chairman of the Compensation Committee of Immunic’s board and serves on the Audit Committee and the Nominating and Corporate Governance Committee.

Dr. Vincent Ossipow

Vincent Ossipow, Ph.D., CFA, joined Immunic’s board in 2017. He is a Partner at the healthcare investment firm of Omega Funds and brings to the Immunic board 20 years of healthcare investment experience in public and private companies. He is member of the Board of Directors of several private and publicly traded life science companies.

Previously, Dr. Ossipow worked as a Partner for Private Equity at Sectoral Asset Management, one of the largest North American healthcare institutional investors. From 2000 to 2006, he was a research fellow at the University of Geneva where he studied the molecular basis of brain function, and acted as Sectoral Asset Management’s Chief Scientific Officer during this period. Previously, he worked at Pictet Bank as a research analyst for biotechnology equities and as a co-manager of the Pictet Biotech Fund, a biotech equities-listed investment vehicle.

Dr. Ossipow trained as a postdoctoral fellow (Hoffman-La-Roche and Human Frontier Science Program fellow) in Geneva and at the National Cancer Institute in Bethesda, MD. He holds a master’s degree in computational sciences, a master’s degree in molecular biology, and a Ph.D. in molecular biology, all from the University of Geneva. Dr. Ossipow holds a CFA (Chartered Financial Analyst) designation from the CFA Institute. He also completed a Certificate in International Finance and Global Markets at the Georgetown University School of Business.

Dr. Ossipow’s work has been published in major journals. He also co-authored the book Monoclonal Antibodies, Methods in Molecular Biology, published in 2014.

He is chairman of the Nominating and Corporate Governance Committee of Immunic’s board and serves on the Audit Committee and the Compensation Committee.

Jan Van den Bossche

Jan Van den Bossche joined Immunic’s board in 2017. He is a Partner at Fund+, a healthcare-focused venture capital firm. Before joining Fund+, Mr. Van den Bossche served on the investor relations team at the Dutch life sciences and materials sciences company DSM, Geleen, The Netherlands, from 2013 to 2015. Previously, he worked for more than 12 years as a biotech analyst at Petercam, where he was involved in several public and private transactions of Belgian and Dutch biotech companies, including ThromoboGenics, Tigenix, UCB, AMT (Uniqure), IBA, and MDxHealth.

Mr. Van den Bossche holds a Bachelor of Economics and a master’s degree in Business Economics from the KU Leuven, Belgium. He also completed the CFA (Chartered Financial Analyst) program at the CFA Institute.

He is chairman of the Audit Committee of Immunic’s board and serves on the Compensation Committee and the Nominating and Corporate Governance Committee.

Dr. Daniel Vitt

Daniel Vitt, Ph.D., joined Immunic in January 2017. Previously, he was Chief Scientific Officer and Chief Development Officer of 4SC AG, a publicly traded company based in Germany that he co-founded in 1997. During his time at 4SC, Dr. Vitt was responsible for all research and development activities and successfully grew the company from the research stage into an advanced therapeutic development company with several clinical-stage product candidates in the pipeline, addressing autoimmune, oncology and infectious diseases. Among these were resminostat, domatinostat and vidofludimus. In 2005, Dr. Vitt took 4SC AG public on the Frankfurt stock exchange.

During his tenure, Dr. Vitt also successfully negotiated and executed several key research and licensing agreements with biotechnology and pharmaceutical companies including Sanofi, LEO Pharma, Yakult Honsha Co., Ltd., Schwarz Pharma and BioNTech AG.

Dr. Vitt studied chemistry in Siegen and Würzburg, Germany, and graduated from the University of Würzburg, where he focused on quantum-chemical calculations of organic reactions. He received his Ph.D. from the Institute of Organic Chemistry at the University of Würzburg, where he focused on molecular design of small molecule therapeutics.

Dr. Vitt is currently a member of the supervisory board of Quattro Research GmbH, a software solutions provider for life science and chemistry applications, located in Planegg, Germany.